Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell ...

XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to ...

Get ready to explore the world like never before! Priceline, the genAI-powered travel innovator, is introducing its Spring 2025 product release, Trip Intelligence: The Neighborhood Edition.

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with ...

Experiencing hair fall is common, but excessive shedding signals underlying issues. Sudden hair loss, thinning, or bald spots warrant attention, potentially indicating conditions like alopecia or ...

The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...

Epilepsy may present as a symptom of many neurological disorders and often an aetiological explanation cannot be identified. There is growing evidence that autoimmune mechanisms might have a role in ...